Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference

Rhea-AI Summary

Decibel Therapeutics (Nasdaq: DBTX) announced that CEO Laurence Reid, Ph.D., will present a corporate overview at the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 a.m. E.T. The presentation will be accessible via a live webcast on the Decibel Therapeutics website, with an archived replay available for 90 days post-event. The company focuses on innovative treatments to enhance hearing and balance, employing a unique platform that integrates single-cell genomics, precision gene therapy, and inner ear biology. Key to their pipeline is DB-OTO, a gene therapy program aimed at addressing congenital hearing loss.

BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will present a corporate overview at the SVB Securities Global Biopharma Conference being held virtually on Thursday, February 16, 2023 at 9:20 a.m. E.T.

A live webcast of the presentation may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com
617-834-0936

FAQ

What is the date and time of Decibel Therapeutics' presentation at the SVB Securities Global Biopharma Conference?

The presentation will take place on February 16, 2023, at 9:20 a.m. E.T.

How can I access the webcast of Decibel Therapeutics' corporate overview?

The live webcast can be accessed on the Decibel Therapeutics website in the Investors section.

What is the main focus of Decibel Therapeutics?

Decibel Therapeutics is dedicated to developing treatments to restore and improve hearing and balance.

What is DB-OTO in Decibel Therapeutics' pipeline?

DB-OTO is a gene therapy program aimed at treating congenital, monogenic hearing loss.

How long will the replay of the Decibel Therapeutics presentation be available?

An archived replay of the presentation will be available for approximately 90 days after the event.